John Minardo 4

What Happened John Minardo, Chief Legal Officer of Ironwood Pharmaceuticals (IRWD), received a grant of 136,612 restricted stock units (RSUs) on March 10, 2026. The Form 4 reports the acquisition price as $0.00 (award/grant). This is a compensation award (not an open‑market purchase or sale).

Key Details

• Transaction date: 2026-03-10; Filing date: 2026-03-12 (filed within the typical 2‑business‑day window).
• Transaction type/code: A — Award/Grant.
• Amount: 136,612 RSUs; reported acquisition price: $0.00.
• Shares owned after transaction: Not disclosed in the provided excerpt of the filing.
• Footnote: The RSU award is an annual performance award that vests 25% of the shares on each approximate anniversary of the grant (i.e., roughly a four‑year vesting schedule).

Context Restricted stock unit grants are compensation and typically vest over time; they do not represent an immediate cash outlay or an open‑market buy/sell. Such awards are common for executive compensation and should be viewed as a remuneration event rather than a direct bullish or bearish trade signal.